July 28, 2015 | Pharmaceuticals giant Merck has agreed to acquire Israeli startup cCAM Biotherapies for $95 million in cash, and up to an additional $510 million, contingent upon certain milestones cCAM is set to reach. Founded in 2010 by Dr. Tehila Ben-Moshe and Dr. Gal Markel, cCAM Biotherapeutics develops immunotherapies to treat cancer.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments